Recent Company News

• 02:13 AM ET May 05, 2025
  

  Nanobiotix presents full results from the completed Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer (€3.05, 0.00)

• 04:23 PM ET Apr 02, 2025
  

  Nanobiotix reports FY net income (€68.1M) vs FactSet (€47.6M) [8 est, (€54.3)-(35.7M)] (€3.20, 0.00)

• 04:23 PM ET Mar 27, 2025
  

  Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC (€3.37, 0.00)

• 04:19 PM ET Mar 20, 2025
  

  NANOBIOTIX announces presentation of data from two phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European lung cancer conference (€3.46, 0.00)

• 09:17 AM ET Mar 18, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:30 AM ET Mar 18, 2025
  

  StreetAccount Summary - US Pre-market trading

• 05:05 AM ET Mar 18, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:33 PM ET Mar 17, 2025
  

  Nanobiotix amends global licensing agreement for JNJ-1900 (€2.95, 0.00)

• 04:52 PM ET Mar 06, 2025
  

  Nanobiotix files $200M mixed shelf; registers up to 5.6M ordinary shares for selling shareholder - F-3 (€3.22, 0.00)

• 08:52 AM ET Feb 14, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market